

**Solasia Announces Non-Clinical Research Results
for Adult T-cell Leukemia / Lymphoma (ATL) of DARINAPARSIN
at Annual Meeting of Japanese Cancer Association**

Tokyo, Japan, October 5th, 2020 - Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia"), a specialty pharmaceutical company based in Japan, today announced that a presentation regarding the results of clinical research in order to investigate the potential of SP-02 (a new anti-cancer drug, international generic name: darinaparsin, hereinafter "darinaparsin") as a therapeutic agent for adult T-cell leukemia / lymphoma (ATL) had been given at "The 79th Annual Meeting of the Japanese Cancer Society" held from October 1 to 3, 2020.

Virtual Oral Presentation:

Abstract No: OJ18-1-4

Abstract title: Examination of effects and the MOA of a new drug candidate, Darinaparsin, on adult T-cell leukemia / lymphoma (ATL) cells

A research group at the University of Tokyo Graduate School and St. Marianna University School of Medicine (Professor Toshiki Watanabe et al.) examined the selective cell death-inducing effect of darinaparsin on ATL cells and human T-cell leukemia virus type 1 (HTLV-1)-infected cells. This research was aimed at elucidating the mechanism of action, and the results had been summarized and presented at the general oral presentation of the 79th Annual Meeting of the Japanese Cancer Society with the title "Investigation of the effect of the new therapeutic drug Darinaparsin on adult T-cell leukemia / lymphoma (ATL) cells and its action and an attempt to elucidate its mechanism"

This study showed the cytotoxic activity of darinaparsin in ATL cell lines, HTLV-1-infected cell lines and ATL patient specimens, suggesting that darinaparsin could be a novel therapeutic agent for ATL.

Darinaparsin is a novel mitochondrial targeting drug (organic arsenic compound) that has been developed for the treatment of various hematological cancers and solid cancers. In the pivotal Phase 2 study of darinaparsin for patients with relapsed or refractory peripheral T-cell lymphoma in Japan, South Korea, Taiwan and Hong Kong, the primary endpoint was achieved in June this year, and currently being prepared for the NDA Filing.

"We are very pleased that the group of Professor Toshiki Watanabe, a world authority on ATL research, has announced the first result of a study on the therapeutic effect of darinaparsin on ATL. The main mechanism of action of darinaparsin is thought to be mitochondrial-mediated tumor cell apoptosis. I hope that this study will elucidate a more detailed mechanism of action of darinaparsin and contribute to future treatment of ATL." said Yoshihiro Arai, President & CEO of Solasia.

###

(Contact)

Solasia Pharma K.K.

Rie Toyoda, Public Relations and Investor Relations

Tel: +81 3 5843 8049 (Japan)

info@solasia.co.jp